0QF.F Moderna Earnings Preview May 1, 2026

Moderna, Inc. (0QF.F) will report first-quarter 2026 earnings on May 1, 2026. Analysts expect the biotechnology company to report revenue of $204.58 million and a loss per share of $3.85. The mRNA vaccine and therapeutics developer faces investor scrutiny over cash burn, pipeline progress, and vaccine demand trends. Moderna’s stock has declined nearly 4% recently, trading at €39.11. The company maintains a market cap of $15.35 billion despite ongoing losses. This earnings preview examines what to expect and key metrics investors should monitor.

Earnings Estimates and Revenue Outlook

Analysts project Moderna will report Q1 2026 revenue of $204.58 million with an earnings per share loss of $3.85. These estimates reflect continued pressure on vaccine sales and ongoing research investments. The company’s trailing twelve-month revenue per share stands at $4.96, indicating significant revenue concentration in recent quarters.

Revenue Expectations

The $204.58 million revenue estimate represents a critical test of Moderna’s commercial execution. The company’s gross profit margin sits at 14.1%, suggesting limited profitability even at higher revenue levels. Investors should monitor whether respiratory vaccine sales, including COVID-19 and flu products, meet expectations or face seasonal demand headwinds.

Loss Per Share Analysis

The projected $3.85 loss per share reflects Moderna’s heavy investment in research and development. The company’s R&D spending represents 161% of revenue on a trailing basis, indicating aggressive pipeline development. With 396.6 million shares outstanding, the company continues burning cash to advance its mRNA platform across multiple therapeutic areas.

Financial Health and Cash Position

Moderna maintains a strong balance sheet despite operating losses, with cash per share of $14.79 and a current ratio of 3.29. The company’s working capital stands at $4.56 billion, providing runway for continued development. However, negative free cash flow of $5.24 per share raises concerns about long-term sustainability without revenue growth.

Liquidity and Debt Management

The company’s debt-to-equity ratio of 0.22 remains manageable, with total debt representing just 11% of market capitalization. Moderna’s interest coverage ratio of negative 3,074 reflects operating losses, but the strong cash position mitigates near-term refinancing risks. The company can sustain current burn rates for several years based on available cash.

Cash Burn Trajectory

Operating cash flow per share of negative $4.72 indicates the company is consuming cash faster than generating it. Free cash flow remains negative at $5.24 per share, driven by capital expenditures and operating losses. Investors should watch whether management provides updated guidance on cash runway and milestone-based spending plans.

Pipeline Progress and Strategic Developments

Moderna’s pipeline spans respiratory vaccines, latent vaccines, cancer immunotherapies, and rare disease treatments. The company has partnerships with AstraZeneca, Merck, Vertex Pharmaceuticals, and the Bill & Melinda Gates Foundation. Q1 earnings will likely include updates on clinical trial progress, regulatory submissions, and partnership developments.

Vaccine Portfolio Performance

The respiratory vaccine franchise includes COVID-19, flu, RSV, and combination candidates. Investors should listen for commentary on vaccine uptake rates, pricing trends, and competitive dynamics. The company’s ability to maintain vaccine revenue while advancing new programs will determine near-term financial trajectory.

Immuno-Oncology and Rare Disease Progress

Moderna’s cancer vaccine programs, including personalized cancer and KRAS vaccines, represent long-term growth opportunities. The company’s systemic and localized therapeutics address cardiovascular and autoimmune diseases. Earnings calls typically provide clinical trial timelines, patient enrollment updates, and regulatory pathway clarity for these programs.

What Investors Should Watch

Moderna’s earnings report will reveal critical information about vaccine demand, cash burn rates, and pipeline advancement. The company’s ability to meet revenue estimates while controlling operating expenses will influence investor sentiment. Key metrics include gross margin trends, R&D spending efficiency, and cash position updates.

Revenue Beat or Miss Probability

Based on the company’s historical operating losses and negative cash flow, meeting the $204.58 million revenue estimate represents a baseline expectation. Investors should focus on whether vaccine sales exceeded or fell short of guidance. Any revenue surprise will likely drive significant stock movement given the company’s valuation multiples.

Guidance and Forward Outlook

Management commentary on 2026 revenue guidance, pipeline milestones, and cash burn rates will shape post-earnings trading. The company’s ability to articulate a path to profitability or sustained revenue growth remains critical. Investors should pay attention to any changes in partnership terms, manufacturing capacity, or market access developments that could impact future results.

Final Thoughts

Moderna’s May 1 earnings report will reveal whether the company can sustain cash burn and drive revenue growth. With expected $204.58 million in revenue and a $3.85 loss per share, investors should focus on clinical progress and cost discipline. The strong balance sheet provides runway, but negative free cash flow requires improved profitability. Meyka AI rates the stock B, reflecting mixed fundamentals. Key metrics to watch include vaccine demand, R&D efficiency, and management’s profitability timeline.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.